摘要
腺昔负荷试验心肌灌注显像诊断冠心病的价值已经得到公认，但其不良反应发生率较高。与腺苷相比，选择性A2。受体激动剂，如regadenoson具有独特优势，目前已完成Ⅲ期临床试验，有可能代替腺苷作为新的负荷试验药物。笔者对腺苷及选择性A2。受体激动剂regadenoson心肌负荷试验作一综述。
Adenosine pharmacological myocardial stress test has been widely used in clinic. How- ever, the side effects related with adenosine administration has been an issue of controversy. Current Phase IU study of regadenoson, a selective A2a receptor agonist, reveals its potential to substitute adenosine as a new agent for pharmacological myocardial stress test. This review briefs adenosine and regadenoson and their clinical utilities in myocardial stress test.
出处
《中华核医学与分子影像杂志》
CSCD
北大核心
2012年第1期75-78,共4页
Chinese Journal of Nuclear Medicine and Molecular Imaging
基金
国家科技支撑计划（2007BA105801）
